- Home
- ANAB vs CII Comparison
ANAB vs CII Comparison
Compare ANAB & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CII
- Stock Information
- Founded
- ANAB 2005
- CII 2004
- Country
- ANAB United States
- CII United States
- Employees
- ANAB N/A
- CII N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CII Investment Bankers/Brokers/Service
- Sector
- ANAB Health Care
- CII Finance
- Exchange
- ANAB Nasdaq
- CII Nasdaq
- Market Cap
- ANAB 759.5M
- CII 879.8M
- IPO Year
- ANAB 2017
- CII N/A
- Fundamental
- Price
- ANAB $13.04
- CII $20.30
- Analyst Decision
- ANAB Buy
- CII
- Analyst Count
- ANAB 11
- CII 0
- Target Price
- ANAB $42.67
- CII N/A
- AVG Volume (30 Days)
- ANAB 775.9K
- CII 78.8K
- Earning Date
- ANAB 11-05-2024
- CII 01-01-0001
- Dividend Yield
- ANAB N/A
- CII 6.17%
- EPS Growth
- ANAB N/A
- CII N/A
- EPS
- ANAB N/A
- CII N/A
- Revenue
- ANAB $57,172,000.00
- CII N/A
- Revenue This Year
- ANAB $233.68
- CII N/A
- Revenue Next Year
- ANAB N/A
- CII N/A
- P/E Ratio
- ANAB N/A
- CII N/A
- Revenue Growth
- ANAB 282.17
- CII N/A
- 52 Week Low
- ANAB $13.00
- CII $16.76
- 52 Week High
- ANAB $41.31
- CII $19.81
- Technical
- Relative Strength Index (RSI)
- ANAB 27.77
- CII 55.91
- Support Level
- ANAB $15.11
- CII $19.44
- Resistance Level
- ANAB $16.74
- CII $20.44
- Average True Range (ATR)
- ANAB 1.48
- CII 0.27
- MACD
- ANAB -0.31
- CII 0.01
- Stochastic Oscillator
- ANAB 0.31
- CII 84.31
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.